Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. results of the CENTAURO antigen dose escalation phase I clinical trial.
Gavilondo JV, Hernández-Bernal F, Ayala-Ávila M, de la Torre AV, de la Torre J, Morera-Díaz Y, Bequet-Romero M, Sánchez J, Valenzuela CM, Martín Y, Selman-Housein KH, Garabito A, Lazo OC; CENTAURO Group of Investigators. Gavilondo JV, et al. Vaccine. 2014 Apr 17;32(19):2241-50. doi: 10.1016/j.vaccine.2013.11.102. Epub 2014 Feb 11. Vaccine. 2014. PMID: 24530151 Clinical Trial.
Active immunization with a structurally aggregated PD-L1 antigen breaks T and B immune tolerance in non-human primates and exhibits in vivo anti-tumoral effects in immunocompetent mouse tumor models.
Morera-Díaz Y, Canaán-Haden C, Sánchez-Ramírez J, Bequet-Romero M, Gonzalez-Moya I, Martínez R, Falcón V, Palenzuela D, Ayala-Ávila M, Gavilondo JV. Morera-Díaz Y, et al. Among authors: gavilondo jv. Cancer Lett. 2023 May 1;561:216156. doi: 10.1016/j.canlet.2023.216156. Epub 2023 Apr 3. Cancer Lett. 2023. PMID: 37019172
Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants.
Sánchez Ramírez J, Morera Díaz Y, Bequet-Romero M, Hernández-Bernal F, Selman-Housein Bernal KH, de la Torre Santos A, Santiesteban Álvarez ER, Martín Bauta Y, Bermúdez Badell CH, de la Torre Pupo J, Gavilondo JV; CENTAURO-2 Team of Investigators; Ayala Avila M. Sánchez Ramírez J, et al. Among authors: gavilondo jv. BMC Immunol. 2017 Jul 26;18(1):39. doi: 10.1186/s12865-017-0222-z. BMC Immunol. 2017. PMID: 28747172 Free PMC article. Clinical Trial.
Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine.
Morera Y, Sánchez J, Bequet-Romero M, Selman-Housein KH, de la Torre A, Hernández-Bernal F, Martín Y, Garabito A, Piñero J, Bermúdez C, de la Torre J, Ayala M, Gavilondo JV. Morera Y, et al. Among authors: gavilondo jv. Vaccine. 2017 Jun 16;35(28):3582-3590. doi: 10.1016/j.vaccine.2017.05.020. Epub 2017 May 20. Vaccine. 2017. PMID: 28536029 Clinical Trial.
Comparative in vitro and experimental in vivo studies of the anti-epidermal growth factor receptor antibody nimotuzumab and its aglycosylated form produced in transgenic tobacco plants.
Rodríguez M, Pérez L, Gavilondo JV, Garrido G, Bequet-Romero M, Hernández I, Huerta V, Cabrera G, Pérez M, Ramos O, Leyva R, León M, Ramos PL, Triguero A, Hernández A, Sánchez B, Ayala M, Soto J, González E, Mendoza O, Tiel K, Pujol M. Rodríguez M, et al. Among authors: gavilondo jv. Plant Biotechnol J. 2013 Jan;11(1):53-65. doi: 10.1111/pbi.12006. Epub 2012 Oct 10. Plant Biotechnol J. 2013. PMID: 23046448 Free article.
44 results